Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRILL: anakinra for hyperinflammation in pediatric oncology patients with sepsis in the ICU
2025-524541-27-00Phase 2Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- May 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of anakinra in sepsis and cytokine release syndrome (CRS) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: 28-day all-cause mortality. Planned start May 2026; status: authorised.
02
Drugs
anakinra
03
Conditions
sepsiscytokine release syndrome (CRS)
Beyond the preview
Go deeper on 2025-524541-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524541-27-00.